Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Effects of Clozapine on Negative Symptoms in Patients with Schizophrenia with Minimal Positive Symptoms

The Effects of Clozapine on Negative Symptoms in Patients with Schizophrenia with Minimal... The effectiveness of clozapine in the treatment of the negative symptoms of schizophrenia remains controversial, as improvements in negative symptoms are invariably accompanied by improvements in positive symptoms and neurological side effects. We examined the effectiveness of treatment with clozapine on negative symptoms in a cohort of patients with minimal positive symptoms. Improvements in positive and negative symptoms were measured by BPRS ratings in a subgroup of schizophrenic patients (n=17, from a state hospital cohort of 75) with minimal positive symptoms, who had received clozapine for 6 months. In this subgroup, significant improvements were noted by a composite score on the three negative symptom items of emotional withdrawal, blunted affect, and motor retardation. Positive and depressive symptoms remained unchanged. The remaining cohort (n=58) showed improvements in overall psychopathology including positive, negative, and depressive symptoms. Interestingly, nearly 50% of each group were discharged from the hospital. These findings suggest that clozapine may be beneficial in the treatment of core negative symptoms, even in the absence of other improvements in psychopathology. This effect of clozapine may be a function of its unique pharmacological profile. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

The Effects of Clozapine on Negative Symptoms in Patients with Schizophrenia with Minimal Positive Symptoms

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/the-effects-of-clozapine-on-negative-symptoms-in-patients-with-yoSEUfuGG0
Publisher
Springer Journals
Copyright
Copyright © 1997 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1022352326334
Publisher site
See Article on Publisher Site

Abstract

The effectiveness of clozapine in the treatment of the negative symptoms of schizophrenia remains controversial, as improvements in negative symptoms are invariably accompanied by improvements in positive symptoms and neurological side effects. We examined the effectiveness of treatment with clozapine on negative symptoms in a cohort of patients with minimal positive symptoms. Improvements in positive and negative symptoms were measured by BPRS ratings in a subgroup of schizophrenic patients (n=17, from a state hospital cohort of 75) with minimal positive symptoms, who had received clozapine for 6 months. In this subgroup, significant improvements were noted by a composite score on the three negative symptom items of emotional withdrawal, blunted affect, and motor retardation. Positive and depressive symptoms remained unchanged. The remaining cohort (n=58) showed improvements in overall psychopathology including positive, negative, and depressive symptoms. Interestingly, nearly 50% of each group were discharged from the hospital. These findings suggest that clozapine may be beneficial in the treatment of core negative symptoms, even in the absence of other improvements in psychopathology. This effect of clozapine may be a function of its unique pharmacological profile.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Sep 18, 2004

References

  • The mechanism of action of novel antipsychotic drugs
    Meltzer, HY
  • The evolution of the serotonin-dopamine antagonist concept
    Huttunen, M
  • Clozapine. A novel antipsychotic agent
    Baldessarini, RJ; Frankenburg, FR
  • Update on the clinical efficacy and side effects of clozapine
    Safferman, A; Lieberman, JA; Kane, JM; Szymanski, S; Kinon, B
  • Psychopharmacologic treatment of schizophrenia
    Kane, JM; Marder, SR
  • The negative symptom challenge
    Carpenter, WT
  • Effects of 6 months of clozapine treatment on the quality of life of chronic schizophrenic patients
    Meltzer, HY; Burnett, S; Bastani, B; Ramirez, LF
  • Deficit and nondeficit forms of schizophrenia
    Carpenter, WT; Heinrichs, DW; Wagman, AM
  • Negative symptoms in schizophrenia: Their longitudinal course and prognostic importance
    Pogue-Geile, MF; Harrow, M
  • Clozapine—A new antipsychotic agent
    Simpson, GM; Varga, E
  • Clozapine (Leponex) compared with chlorpromazine: A double-blind evaluation of pharmacological and clinical properties
    Ekblom, B; Haggstrom, JE
  • Clozapine and haloperidol in a single-blind cross-over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia
    Gerlach, J; Koppelhus, P; Helweg, E; Monrad, A
  • A double-blind comparison of clozapine (Leponex) and chlorpromazine in schizophrenia of acute symptomatology
    Singer, K; Law, SK
  • Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness
    Chiu, E; Burrows, G; Stevenson, J
  • An example of European multicenter trials: Multispectral analysis of clozapine
    Fischer-Cornelssen, KA; Ferner, UJ
  • Clozapine (Leponex) vs chlorpromazine (Largactil) in acute schizophrenia (a double-blind controlled study)
    Guirguis, E; Voineskos, G; Gary, J; Schlieman, E
  • Clozapine versus chlorpromazine for the treatment of schizophrenia: Preliminary results from a double-blind study
    Gelenberg, AJ; Doller, JC
  • Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: A controlled, double-blind comparison
    Shopsin, B; Klein, H; Aaronsom, M; Collora, M
  • The risks and benefits of clozapine versus chlorpromazine
    Claghorn, J; Honigfeld, G; Abuzzahab, F. S.; Wang, R; Steinbook, R; Tuason, V; Klerman, G
  • Clozaril collaborative study group: Clozapine for the treatment resistant schizophrenic. A double-blind comparison with chlorpromazine
    Kane, JM; Honigfeld, G; Singer, J; Meltzer, H
  • Clozapine in the treatment of 121 out-patients
    Leppig, M; Bosch, B; Naber, D; Hippius, H
  • Clozapine for refractory schizophrenia: An open study of 14 patients treated up to 2 years
    Mattes, JA
  • A prospective study of clozapine in treatment resistant schizophrenic patients
    Meltzer, HY; Bastani, B; Young-Kwon, K; Ramirez, LF; Burnett, S; Sharp, J
  • Clinical and biological response to clozapine in patients with schizophrenia
    Pickar, D; Owen, RR; Litman, RE; Konicki, PE; Gutierrez, L; Rapaport, MH
  • Clozapine-induced weight gain: Prevalence and clinical relevance
    Leadbetter, R; Shutty, M; Pavalonis, D; Vieweg, V; Higgins, P; Downs, M
  • The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK
  • The use of clozapine in treatment-refractory schizophrenia
    Kuoppasalmi, K; Rimon, R; Naukkarinen, H; Lang, S; Sandqvist, A; Leinonen, E
  • Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns
    Breier, A; Buchanan, RW; Irish, D; Carpenter, WT
  • Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
    Breier, A; Buchanan, RW; Kirkpatrick, B; Davis, OR; Irish, D; Summerfelt, A; Carpenter, WT
  • Clozapine response varies in deficit versus non-deficit schizophrenic subjects
    Conley, R; Gounaris, C; Tamminga, C
  • Clozapine effects on positive and negative symptoms: A six-month trial in treatment-refractory schizophrenics
    Lindenmayer, JP; Grochowski, S; Mabugat, L
  • Clozapine's effect on negative symptoms in treatment-refractory schizophrenics
    Miller, DD; Perry, PJ; Cadoret, RJ; Andreasen, NC
  • Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome
    Lieberman, JA; Safferman, AZ; Pollack, S; Szymanski, S; Johns, C; Howard, A; Kronig, M; Bookstein, P; Kane, JM
  • Clozapine and refractory schizophrenia. Long-term prospective study of 20 patients
    Jalenques, I; Coudert, AJ
  • The brief psychiatric rating scale
    Overall, JE; Gorham, DR
  • Negative symptoms in schizophrenia
    Andreasen, NC
  • The Scale for the Assessment of Positive Symptoms (SAPS)
    Andreasen, NC
  • Construction of a new psychiatric rating instrument, the comprehensive psychopathological rating scale (CPRS)
    Asberg, M; Schalling, D
  • The positive and negative syndrome scale (PANSS) for schizophrenia
    Kay, SR; Fizbein, A; Opler, LA
  • Patient response and resource management: Another view of clozapine treatment of schizophrenia
    Carpenter, WT; Conley, RR; Buchanan, RW; Breier, A; Tamminga, CA
  • Clozapine: Is another view valid?
    Meltzer, HY
  • Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review
    Rao, ML; Moller, HJ
  • Important issues in the drug treatment of schizophrenia
    Davis, JM; Schaffer, CB; Killian, GA; Kinard, C; Chan, C
  • Clozapine, negative symptoms and extrapyramidal side-effects
    Kane, JM; Safferman, AZ; Pollack, S; John, C; Szymanski, S; Kronig, M; Lieberman, JA
  • A clinical guide to antipsychotic drugs
    Schwartz, JT; Brotman, AW
  • A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia
    Singh, MM; Kay, SR
  • EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics
    Roubicek, J; Major, I
  • Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression
    Ranjan, R; Meltzer, HY
  • The frontal lobes and schizophrenia
    Weinberger, DR; Aloia, MS; Goldberg, TE; Berman, KF
  • Preferential activation of cortical dopamine neurotransmission by clozapine: Functional significance
    Moghaddam, B
  • Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics
    Ereshefsky, L; Tran-Johnson, TK; Watanabe, MD
  • Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile
    Meltzer, HY; Gudelsky, GA
  • Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors
    Leysen, JE; Janssen, PM; Schotte, A; Luyten, WH; Megens, AA
  • New perspectives on biological treatment of schizophrenia
    Lingjaerde, O
  • Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications
    Carpenter, WT; Conley, RR
  • Deficit and non-deficit forms of schizophrenia: The concept
    Carpenter, WT; Heinrichs, DW; Wagman, AMI